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a  b  s  t  r  a  c  t
A  recently  published  model  for the serum  antibody  response  to infection  appeared  well  suited  for use
in  statistical  analyses  of  longitudinal  serological  data.  The  published  model  assumed  exponential  decay
with ﬁxed  rates  for pathogen  and  serum  antibody  kinetics,  ignoring  any  within-host  heterogeneity  in
the  seroresponse.  A bi-exponential  model  shows  that there  is  rapid initial  decay  followed  by  a prolonged
period  of persistent  low  serum  antibody  concentrations.  We  propose  a small  modiﬁcation  of  the decay
model  that greatly  increases  its  ﬂexibility  by allowing  for non-exponential  antibody  decay.
The modiﬁed  model  produces  power  functions  that  may  be  interpreted  as  a  mixture  of  exponen-
tial  decay  curves,  with a mixing  distribution  representing  the  relative  contribution  of many  centres  of
antibody  production  to the  serum  antibody  concentration.
Fitting  the power  function  decay  model  to  observed  longitudinal  data  for pertussis  shows  improved
arameter estimation goodness  of ﬁt  compared  to the  exponential  decay  model,  with  estimates  for  the  shape  parameter  (r  = 2.2;
95%  CI (1.7–2.8))  that  differ  from  exponential  shape  (r =  1).
The power  function  decay  model  predicts  more  persistent  antibody  concentrations  in  the  long term
(symptomatic  threshold  reached  >30 years  after  infection)  which,  when  used  in biomarker  studies,  will
lead to lower  estimates  of seroconversion  rates  compared  to  exponential  antibody  decay.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
The kinetics of serum antibodies as observed in longitudinal
tudies of (symptomatically) infected subjects (Teunis et al., 2002;
ersteegh et al., 2005; Strid et al., 2001, 2007) have been described
y dynamic mathematical models that assume some form of inter-
ction between pathogens and antibodies (Simonsen et al., 2009;
erbers et al., 2013): antigens from colonizing pathogens activate
ntibody production, and the circulating antibodies (directly or
ndirectly) inactivate pathogens and inhibit their growth.For successful application of such models of the serum anti-
ody response to infection, simplicity not only is enforced by
he complex dynamics, but also can be an advantage: ideally, a
∗ Corresponding author at: Centre for Infectious Disease Control, RIVM, Bilthoven,
etherlands.
E-mail address: peter.teunis@emory.edu (P.F.M. Teunis).
ttp://dx.doi.org/10.1016/j.epidem.2016.04.001
755-4365/© 2016 The Authors. Published by Elsevier B.V. This is an open access
y-nc-nd/4.0/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
within-host model provides an explicit mathematical expression
for the time course of serum antibody concentrations, while pre-
serving a biological meaning (Casadevall and Pirofski, 2001).
In a previous paper a within-host model was formulated (de
Graaf et al., 2014), assuming that the serum antibody response to
infection consists of two  episodes: ﬁrst a period of colonization
where antibodies interact and inactivate pathogens, followed by
a second period of serum antibody decay, where antibodies are
slowly removed and their concentration in serum returns to zero.
Upon infection, a number of pathogens enters the host (and
their antigens are detected by the host immune system). These
pathogens start growing and an immune response is activated,
resulting in growth of antibody producing cells, and activation of
antibody production in these cells. This may  result in antibody
production that increases as a double exponential function with
time (Asachenkov et al., 1994). Such explosive increase in antibody
concentrations can only last for a brief period and for simplic-
ity we remain with the assumption of exponential production of
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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ntibodies, that inactivate the newly grown pathogens, during the
nfection episode.
In acute (not chronic) infection in an immunocompetent host
he immune response clears infection, and the result is removal of
ll pathogens. As soon as the pathogen concentration reaches zero,
ntigen associated stimulation of antibody production stops and
ecay becomes dominant. As a consequence the net concentration
f serum antibodies decreases with time.
This simpliﬁed model of the serum antibody response appears
exible and can be easily implemented into multilevel frameworks
sing Markov chain Monte Carlo methods (de Graaf et al., 2014).
ere we will show that a minor change in this model allows for
uantitative assessment of within-host heterogeneity in antibody
roduction rates. By assuming a continuous function for describ-
ng the variation in antibody kinetics among a great number of
roduction sites, the model can be made even more ﬂexible.
. Multisite model for antibody production
Suppose there are multiple (K) compartments (hereafter called
production sites’) where antibodies are produced, each with their
wn kinetics, after which these antibodies are transferred into a
ingle, shared compartment, where the antibodies may  interact
ith antigens (pathogens) and from where antibodies are removed
turnover). For simplicity, we assume that the blood stream repre-
ents the shared compartment, where the antibody concentration
s measured. The model formulated earlier (de Graaf et al., 2014) is
hen modiﬁed to
Infection/colonization episode Waning immunity episode
b′(t) = 0b(t) −
K∑
k=1
ckyk(t) b(t) = 0
y′
k
(t) = ∗
k
yk(t) − 0yk(t) y′k(t) = w∗kyk(t) − 0yk(t)
(1)
In the above model, b(t) is a measure for the antigen (pathogen)
oncentration and yk(t) is a measure for the serum antibody concen-
ration at production site k (k = 1, 2, . . .,  K). Upon infection at time
ero, b(0) is set to some positive value b0, the (effective) inoculated
ose. At that time, the antibody concentration in the shared com-
artment y(0) is at some positive baseline value y0 resulting from
 previous infection. Numbers of pathogens grow with an intrin-
ic rate 0, the inactivation of pathogens effected by antibodies
rom these multiple sources is represented by the weighted sum
kckyk(t), ck being a measure of the strength of the contribution
rom production site k (ck ≥ 0, ∀k). During infection, the antibodies
roduced from any site k increase with rate ∗
k
. At any time anti-
odies are removed from the shared (blood) compartment. This
urnover of antibodies is assumed to occur with a ﬁxed rate 0, so
hat for site k the net rate of exponential increase is k = ∗k − 0.
uring the infection episode with stimulated antibody production
t is assumed that k > 0 for all production sites (k = 1, b, . . .,  K).
ost infection, during the waning immunity episode (when b(t) = 0)
ntibodies are produced with rate w∗
k
, and it is assumed that the net
ate −wk = w∗k − 0 < 0 for all k compartments (any compartment
ith net rate >0 would result in long term increase in antibody
oncentrations). We  can therefore write
Infection/colonization episode Waning immunity episodeb′(t) = 0b(t) −
K∑
k=1
ckyk(t) b(t) = 0
y′
k
(t) = kyk(t) y′k(t) = −wkyk(t)
(2)ics 16 (2016) 33–39
Pathogen concentrations change as
b(t) =
⎧⎪⎨
⎪⎩
b0e0t −
K∑
k=1
cky0,k
(
e0t − ekt
)
0 − k
(t < t1)
0 (t ≥ t1)
(3)
and the serum antibody concentration is the sum of contributions
from all production sites.
Although an explicit expression cannot be obtained for the point
in time t1 when the pathogen concentration reaches zero, the
antibody concentration peaks at that same time t1, because at all
production sites antibody concentrations increase monotonically
prior to t1 and decrease monotonically after t1. If the peak antibody
concentration for site k is y1,k then
y(t) =
K∑
k=1
yk(t) =
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
K∑
k=1
y0,ke
kt (t < t1)
K∑
k=1
y1,ke
−wk(t−t1) (t ≥ t1)
(4)
Before time t1 antibodies are produced as a set of K exponentially
increasing contributions to the concentration in serum. At t1 the
observable peak serum antibody concentration from Eq. (4) is
y(t1) =
K∑
k=1
y1,k = y1 (5)
After t1 antibodies decay only, with different net decay rates wk
at each site. Contributions from different antibody production sites
may  vary during infection (t < t1) and during the waning immunity
episode (t ≥ t1) as the population of antibody producing (B) cells is
not stationary (Amanna and Slifka, 2010).
2.1. Two sites
In the above model, heterogeneity in serum antibody produc-
tion was  represented by the set of K antibody production sites,
each with their own  contribution to the antibody concentration
in serum, during infection and waning immunity. Although per-
haps more realistic than the simple model in de Graaf et al. (2014),
practical application in models for estimating seroconversion rates
requires a simpler model with fewer parameters, so that there are
no problems with parameter identiﬁcation and estimation is pos-
sible.
During the infection phase, antibody increase tends to be dom-
inated by the production sites with the highest rate of increase.
Shortly after inoculation, antibody increase is expected to increase
exponentially, even in the presence of heterogeneity in production.
Conversely, after infection has cleared, production sites with rela-
tively rapid decay cease to contribute early during the decay phase
of the seroresponse, leaving those sites where decay is relatively
slow for sustaining long term antibody presence in circulation. Het-
erogeneity in antibody production kinetics therefore is expected to
cause detectable deviations from simple exponential kinetics only
during the decay phase of the seroresponse.
Suppose there are two  populations of antibody producing cells
(Amanna and Slifka, 2010), each with their own  discrete decay rate,
˛0 and ˛1, so that decay is bi-exponential
y(t > t1) = (1 − )e−˛0(t−t1) + e−˛1(t−t1) (6)
with proportion  indicating the relative contributions of either
cell population to the circulating antibodies. If ˛0  ˛1 then there is
rapid initial decay with rate (approximately) ˛0, followed by a slow
decay phase with rate ˛1. Existence of two  different decay rates
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as been attributed to the presence of two different populations of
ntibody producing cells (Slifka et al., 1995, 1998).
.2. Many sites
Although there may  be two different cell types involved in
erum antibody production, this does not imply that their decay
ates may  be governed by only two ﬁxed rates. We  assume that
mong these two cell populations there is a large number of anti-
ody production sites (Stromberg et al., 2013). Such sites may  be
egions in the antibody producing tissues, but could also represent
ndividual antibody producing cells, or even intracellular compart-
ents where antibody production takes place.
Eq. (4) describes the serum antibody concentration as a sum of
ontributions from sites with decay rate wk and (initial) strength
1,k. Without sacriﬁcing generality the pairs (y1,k, wk) may  be
rranged, by increasing wk. The joint serum antibody concentration
ay  then be approximated as
() =
K∑
k=1
y1,ke
−wk() ≈
∫ ∞
x=0
y1(x)e−w(x)dx (7)
ssuming many production sites (K → ∞).  The time from peak level
 = t − t1 and y1(x) is the contribution to y1 dependent on some
ontinuous variable x ∈ (0, ∞),  with w(x) a strictly increasing con-
inuous function describing how the decay rate depends on x. Thus,
(x) is invertible and x can be expressed as a function of w.
With a change of variable
() =
∫ w(∞)
w(0)
y1 (x(w)) e−w
(
dw
dx
)−1
dw (8)
e may  write
() = y1
∫ w(∞)
w(0)
y1(x(w))
y1
(
dw
dx
)−1
e−wdw = y1
∫ ∞
w=0
f (w)e−wdw
(9)
here y1 is the peak serum antibody concentration as deﬁned in
q. (5) and
 (w)  = y (x(w))
y1
(
dw
dx
)−1
(10)
o that
∫ ∞
0
f (w)dw = 1. Thus, f (w)  may  be interpreted as a prob-
bility density, describing the distribution of antibody decay rates
mong production sites.
It may  be noted that for the infection episode, a similar argu-
ent for heterogeneous antibody production may be developed.
evertheless, collection of blood samples very early during infec-
ion is rare, so that there usually is little empirical information from
erum antibody data for the shape of the antibody increase dur-
ng infection. Because the production site with fastest exponential
ncrease will rapidly dominate joint antibody production, we per-
ist to assume the simplest possible case of exponential increase.
.3. Heterogenous antibody decay
The Gamma  distribution is a popular model for describing vari-
tion in rates (Thorne and Kishino, 2002; Huelsenbeck et al., 2001;
yke and Thompson, 1986). If f (w) is a gamma  probability density
shape ˛, scale ˇ) then
( > 0) = y1
(
1 + ˇ
)−˛
(11)ics 16 (2016) 33–39 35
using the moment generating function of the gamma distribution.
Antibody decay thus can be described as a power function, instead
of exponential decay. Taking the derivative in Eq. (11)
y′() = −˛ˇy−1/˛1 y()
1+1/˛ (12)
This motivates a slightly more general model, derived from de
Graaf et al. (2014). Consider the following model:
Infection/colonization episode Waning immunity episode
b′(t) = 0b(t) − cy(t) b(t) = 0
y′(t) = y(t) y′(t) = −y(t)r
(13)
if f (w)  would be a gamma  distribution, then r = 1 + 1/˛  and  =
˛ˇy−1/˛1 .
The left part of the model, describing the dynamics of pathogen
concentration b(t) and serum antibody concentration y(t) during
the infection episode, remains identical to the published model (de
Graaf et al., 2014).
However, addition of only a single parameter to the model for
the waning immunity episode profoundly changes antibody decay.
From t = t1 antibody decay proceeds as
y(t > t1) = y1(1 + (r − 1)yr−11 (t − t1))
−1/(r−1)
(14)
When the shape parameter r > 1, initial decay is more rapid than
exponential, followed by a period of slower than exponential decay.
Note that for the limit r ↓ 1 (i.e. the limit to exponential decay of
the antibody concentration)  ˛ → ∞ and the function f (w) → ı(w −
). Here ı refers to the Dirac delta function. Therefore, when r ↓ 1,
w =  with probability one. Also note that the peak concentration
y1 depends on the scale parameter ˇ: the function f (w)  in Eq. (9)
deﬁned the relative contributions of sites to the serum antibody
concentration in the shared compartment.
In summary the following response is obtained, for pathogens
b(t) and for antibodies y(t)
b(t) =
⎧⎪⎨
⎪⎩
t ≤ t1 : b0e0t −
cy0
(
et − e0t
)
 − 0
t > t1 : 0
y(t) =
⎧⎪⎨
⎪⎩
t ≤ t1 : y0et
t > t1 : y1(1 + (r − 1)yr−11 (t − t1))
−
1
r − 1
(15)
It follows (de Graaf et al., 2014) that
t1 =
1
 − 0
log
(
1 + ( − 0)b0
cy0
)
(16)
2.4. Parameter estimation
Although all parameters in the model in Eqs. (15) or (6) may
have a biological meaning, they cannot all be estimated when only
serum antibody data are available.
The serum antibody response to infection is completely charac-
terized by the baseline level y0, the peak level y1, the time to peak
t1, and the decay parameters  and r. Given the above parameters,
the rate of antibody increase during infection may be calculated
 = 1
t1
log
(
y1
y0
)
(17)
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The reduced parameter c0 = c/b0 (de Graaf et al., 2014) and the
athogen growth rate 0 cannot be estimated, only their relation
an be expressed as
0 =
 − 0
y0(e(−0)t1 − 1)
(18)
When the data contain little information on the shape of the
esponse during infection, estimating y1 and t1 has the advantage
hat these two parameters may  be speciﬁed as a plausible range,
s prior information in the model ﬁtting procedure. The pertus-
is data used here and in de Graaf et al. (2014) do not require
uch informed priors because they include observations during
he infection episode. In other studies capturing such early serore-
ponse data may  not be possible (Simonsen et al., 2009; Teunis et al.,
012).
. Results: application of the within host model
The code for ﬁtting the two-phase seroresponse model (de Graaf
t al., 2014) to serum antibody data has been modiﬁed to include
lternative decay functions, either bi-exponential or power func-
ion decay. Thus modiﬁed, the seroresponse model can now be used
o analyze serum antibody data for natural infection by Bordetella
ertussis. The model was implemented in JAGS (Plummer, 2003).
etails of parameter estimation and prediction of antibody concen-
rations as given in de Graaf et al. (2014) remain the same, except for
he addition of the parameters describing non-exponential decay
, ˛1 and ˛2, or  and r). See Appendix for more details.
.1. Changes in predicted antibody responses
Both non-loglinear decay models result in improved ﬁt, as
udged by the smaller residuals compared to the simple exponential
ecay model, Fig. 1. Parameter estimates for the updated serore-
ponse models are given in Table 1. Predicted responses from the
pdated model can be compared with previous output (Fig. 2),
Fig. 1. Residuals for the three models f
Table 1
Estimated parameter values for the updated seroresponse mode
antibody concentration y1; time to peak t1. For bi-exponential d
proportion parameter . For power function decay: decay rate par
Mean Median 
Bi-exponential decay
y0 2.03 1.99 
y1 1.65 0.86 
t1 3.89 3.07 
˛0 2.42 1.65 
˛1 4.93 3.73 
  7.50 7.15 
Power function decay
y0 1.87 1.83 
y1 7.76 1.23 
t1 3.69 3.14 
  1.49 0.92 
r  2.19 2.16 ics 16 (2016) 33–39
showing that both models provide a better ﬁt to the early stages
of serum antibody decay. Initial rapid decay within the ﬁrst year
post-infection is followed by an extended period of slower decay.
Also, the predicted intervals are narrower for the power function
model, more closely following the observed antibody concentra-
tions (Fig. 2c). It is interesting to see that when a third exponential
decay function is added, the predicted intervals tend towards those
of the power function decay model (Appendix, Fig. A3).
In addition to the four characteristic features of the serore-
sponse: baseline antibody concentration, time to peak, peak
antibody concentration, and rate of antibody decay, the power
function model adds a ﬁfth parameter: the shape parameter of anti-
body decay. As Table 1 shows, the shape parameter differs from
exponential (r = 1), it is close to 2.
3.2. Heterogeneity in serum antibody decay
From the estimated parameters for the pertussis serum antibody
reponse, the distribution of decay rates among antibody production
sites may  be calculated.
This can be done for the exponential model, simply as a density
graph of the posterior sample for the decay rate ˛. This illustrates
(posterior) uncertainty in  ˛ (Fig. 3a). Similarly, using the poste-
rior samples of the two  decay rates ˛0 and ˛1 in the bi-exponential
model, and weighting these by the proportion (1 −  and , respec-
tively), the uncertainty in the decay rate for the bi-exponential
model can be shown (Fig. 3b). For the power function model, the
variation in decay rate among antibody producing sites is repre-
sented by the gamma  distribution deﬁned by (scale)  and (shape)
r (Fig. 3c).
These distributions are highly skewed, indicating strong het-
erogeneity, so that graphing the 10log of the decay rates more
clearly shows the shape of its distribution (Fig. 3d–f). The decay rate
appears to vary over four orders of magnitude, ranging from 0.5 to
0.0005 day−1. Note that in Fig. 3c and f shading density represents
or the serum antibody response.
l: baseline (pre-infection) antibody concentration y0; peak
ecay: rapid initial decay rate ˛0; slow ﬁnal decay rate ˛1;
ameter ; shape parameter r.
95% predictive interval Units
1.28–3.02 × 10−1 IU/ml
0.09–8.12 × 103 IU/ml
0.82–12.33 × 101 days
0.35–9.34 × 10−2 1/days
0.67–16.12 × 10−4 1/days
3.75–12.84 × 10−2
1.08–2.94 × 10−1 IU/ml
0.03–50.92 × 103 IU/ml
0.96–9.49 × 101 days
0.12–6.18 × 10−5 1/days
1.74–2.82 × 100
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Fig. 2. Nonlinear decay of IgG-PT antibody concentrations in serum of symptomatic patients (Versteegh et al., 2005). (a) Exponential antibody decay (de Graaf et al., 2014);
( redic
s
q
a
3
s
s
o
i
t
8
o
t
F
(
(b)  bi-exponential decay; (c) power function decay. All graphs show contours of p
hown  are observed data: repeated observations of subjects are connected.
uantiles, with median in black and lighter shades indicating lower
nd higher percentiles of the posterior density.
.3. Antibody persistence
Having identiﬁed a persistent fraction of antibody production
ites, it is also of interest to look at persistence of antibodies in
erum (Fig. 4). When using the power function decay model, 20%
f infected cases have antibody concentrations below 100 IU/ml
mmediately following infection, 80% of subjects still have concen-
rations above 10 IU/ml 10 years later, and 30 years post-infection
0% would still be above 5 IU/ml, close to the symptomatic thresh-
ld estimated in de Graaf et al. (2014). Assuming, of course, that
here are no re-infections during that period.
ig. 3. Distribution of serum antibody decay rates w estimated from observed IgG-PT con
uncertainty) of the ﬁxed decay rate (w = ˛) in the exponential decay model; (b) posterior de
c)  posterior density of the distribution of w in the power function model (shading illustrted IgG-PT concentrations (10log-scale), median and 95% predictive interval. Also
4. Discussion
The addition of only a single parameter changes the serore-
sponse model of de Graaf et al. (2014) so that an initial period
of rapid decay may  be followed by a prolonged period with slow
decay, possibly representing immunological memory. The method
used here therefore achieves responses similar (but not identical) to
bi-exponential models, that assume two discrete exponential decay
phases, with one additional parameter instead of two (that is, a sec-
ond decay rate and a mixing parameter). Arguably, a distribution
of (many different) decay rates is a more realistic description of the
heterogeneity resulting from within-host variation in antibody pro-
duction than occurrence of exactly two discrete decay rates. Such
a discrete class decay model may  not be robust. When ﬁtted to
serum antibody data that would imply simple exponential decay,
centrations in symptomatic patients (Versteegh et al., 2005). (a) Posterior density
nsity (uncertainty) of decay rates in the bi-exponential model (w = (1 − )˛0 + ˛1);
ates uncertainty). (d), (e) and (f) show the same for 10log(w).
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sig. 4. Persistence of IgG-PT serum antibodies estimated by the exponential (expon
gG-PT  concentrations above a protective threshold level of 5 or 20, IU/ml, versus ti
he parameters deﬁning the additional decay rate cannot be iden-
iﬁed. For such data the power function model is well behaved.
s the shape parameter r approaches 1 the seroresponse curve
pproaches exponential decay. The increased ﬂexibility makes this
odel suitable for ﬁtting to (longitudinal) serum antibody data.
Nevertheless, the power function decay curves produced by the
odel proposed here can be interpreted as a mixture of exponen-
ial decay curves, with a mixing distribution that may  be estimated.
pplying this model to longitudinal serum antibody data therefore
llows estimation of both within-host and between host hetero-
eneity in seroresponses.
It seems attractive to model non-exponential decay as a mixture
f simple exponential decay curves, with different rate constants.
ote must be taken however, that the serum antibody response
esults from the host immune response, as one observable output
f a complex regulated signalling network (Thakar et al., 2007).
Production of (serum) antibodies may  be driven by several
ifferent mechanisms that sequentially activate and deactivate
Traggiai et al., 2003), resulting in complex decay curves that devi-
te from simple exponential shapes.
It must be noted that during the infection episode, hetero-
eneity in antibody production must be present as well as during
he post-infection episode. Although in all likelihood, deviations
rom exponential increase in antibody concentrations cannot be
etected, the interaction term describing pathogen inactivation
ckyk(t) in Eq. (2) may  cause pathogen decay different from the
imple model in Eq. (15), because of the weighting factors ck. Since
here currently is no means of characterizing such heterogeneity
e have chosen to not include it and keep the simple model pro-
osed by de Graaf et al. (2014). At least essential properties of rapid
rowth followed by rapid die-off of pathogens are thus preserved. A
otentially interesting alternative could be to assume that the post-
nfection distribution of decay rates is also valid for the distribution
f variation in antibody production during infection, but with a
ifferent scale factor, causing net production instead of decay.
The seroresponse to natural infection with Bordetella pertus-
is decays non-exponentially, with an estimated shape parameter
lightly above 2. This implies strong heterogeneity in post-infection
ntibody production: a small fraction of antibody producing sites
cells) tends to maintain production for decades after a boosting
vent. Fig. 4 shows that allowing for power function decay leads to
uch slower decrease in antibody concentrations, than obtained
ith exponential decay models. This slowdown in antibody decay
s quite inﬂuential when estimating the duration of protection from
erum antibody levels, as illustrated in Fig. 4. The tailing off of thei-exponential (biexpon) and the power function (powfunc) decay models. Fraction
llowing (natural) infection.
decay curve means that low antibody levels are persistent, for long
periods. And, as the present study has argued, these persistent lev-
els may  be interpreted as a fraction of involved sites keeping up
antibody production for a long period.
The long term presence of low antibody concentrations, long
after infection, is also relevant for biomarker applications of
serum antibodies (Teunis et al., 2012). Here the antibody con-
centrations in a cross-sectional population sample are used to
estimate the rate with which seroconversions occur: the higher
the seroconversion (infection) rate, the more frequent high anti-
body concentrations are detected. More persistent antibodies lead
to lower estimates of the seroconversion rate, as any low concen-
tration in the cross-sectional sample corresponds to a longer time
since seroconversion, compared to the estimate from the exponen-
tial decay model.
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